FindTrial
Sign In

J2S-MC-GZMS: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Brenipatide in the Treatment of Adult Participants with IBS-D

Status
Not yet recruiting
Phases
Phase 2
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2025-524973-17-00
Enrollment
40
Registered
2026-08-20
Start date
Unknown
Completion date
Unknown
Last updated
2026-08-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Irritable Bowel Syndrome Diarrhea

Brief summary

Percentage of Participants Who Had a Daily Composite Response for at Least 50 Percent (%) of Days.

Interventions

DRUGPlacebo to match LY
DRUGBrenipatide

Sponsors

Eli Lilly & Co.
Lead SponsorINDUSTRY

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Design outcomes

Primary

MeasureTime frame
Percentage of Participants Who Had a Daily Composite Response for at Least 50 Percent (%) of Days.—

Outcome results

None listed

Source: EU CTIS · Data processed: Aug 21, 2026